Skip to main content
# Title Department Research Member Research Year
51 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Amany Mohammed Abdel Moatamed 2024
52 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Prof. Ashraf Zeidan Abdalla Ahmed 2024
53 Beta Endorphins, Interleukin 1 and Interleukin 38 in Covid Patients Associated with Neuropsychological Manifestations Department of Clinical Pathology Dr. Engy adel shafeek 2024
54 Factors affecting timing of hypothyroidism following radioactive iodine therapy (RAIT) for patients with Graves' disease: A 12-month observational study Department of Radiotherapy and Nuclear medicine ِAya AbdelBaset Ahmed 2024
55 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Dr. Shimaa Hassan Shabaan Hassan 2024
56 Family strategies formanaging childhood cancer: Using traditional and complementarymedicine in Southern Egypt Department of Pediatric Oncology Ahmed Abdelwahab Faraag Mohammed 2024
57 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Dr. Salah Mabrouk Khallaf Abd Rabou 2024
58 Prognostic Value of Erythropoietin-Producing Hepatocellular Receptor A2 (Epha2) Serum Marker in Colorectal Cancer Department of Medical Oncology Dr. Amen Hamdy Zaki Ali 2024
59 TheUseofTraditional and Complementary Medicine by Children with Cancer in Jordan Department of Pediatric Oncology Ahmed Abdelwahab Faraag Mohammed 2024
60 FOXP3 Expression as a Biomarker in Metastatic Colorectal Cancer Treated with Irinotecan-based Therapy Department of Medical Oncology Dr. Shimaa Hassan Shabaan Hassan 2023